Researchers at the University of Notre Dame have discovered a way to make influenza visible to the naked eye, according to a new study in the Journal of the American Chemical Society.
By engineering dye molecules to target a specific enzyme of the virus, the team was able to develop a test kit that emitted fluorescent light when illuminated with a hand-held lamp or blue laser pointer.
Scientists used test samples that mimicked that of an infected patient, and spiked the samples with the enzyme, called neuraminidase, which had been purified from flu virus. The samples emit red fluorescent light as a positive indication of the influenza virus. Blue fluorescent light signals a negative result. The same process also allowed scientists to determine which of two approved antiviral drugs would be a better treatment option for the individual patient.
While still a prototype, researchers believe that with optimization the diagnostic could be developed to be used in point of care clinics or the home environment for a rapid, easy to interpret test for the presence of influenza.
“Viral cultures are the gold standard for diagnosis of influenza but take several days to develop. By targeting an enzyme inherent to the virus and identifying its presence in a sample, we can make a rapid determination of the influenza in a patient for an efficient and immediate diagnostic that would improve patient treatment and reduce overuse of antivirals,” said Bradley Smith, Emil T. Hofman Professor of Chemistry and Biochemistry in the Department of Chemistry and Biochemistry, director of the Notre Dame Integrated Imaging Facility and co-author of the study.
Smith and his team created a new method to detect neuraminidase, which is located on the surface of the virus. Researchers began by designing a dye molecule to emit red fluorescent light when it interacts with the neuraminidase. Following validation of enzyme recognition, researchers then tested the dye with two antiviral drugs used to treat influenza — Zanamivir, also known as Relenza, and Oseltamivir, known widely as Tamiflu. The antivirals are neuraminidase inhibitors. Samples containing dye and neuraminidase were combined with each of the antivirals and illuminated. Red fluorescence indicated the enzyme was still active, meaning the antiviral failed to inhibit the virus in that patient. Blue light indicated the enzyme had been blocked, presenting an effective treatment option.
The study, which received funding from the National Science Foundation and Notre Dame’s research initiative, Advanced Diagnostics and Therapeutics, focused specifically on fluorescence detection of the virus and efficacy of the two inhibitors. Smith’s team hopes to build upon these results in the future.
The Latest on: Influenza diagnostic
- Mesa Biotech Obtains CE Mark for its Accula RSV Molecular Point of Care Test on November 13, 2018 at 4:43 am
The Center for Disease Control (CDC) acknowledges that the specificity and sensitivity of rapid influenza diagnostic tests (RIDT) are lower than for viral culture and RT-PCR and vary by test. The Accu... […]
- U.S. Influenza Diagnostics Market Worth USD 865.4 Million by 2024: Hexa Research on November 13, 2018 at 3:48 am
Rising demand for faster diagnosis of influenza as a result of growing disease prevalence is expected to foster market growth over the forecast period. In addition, new product developments and ... […]
- Rapid Influenza Diagnostic Tests Market 2017 Share, Growth, Trend Analysis And Forecast to 2021; Consumption Capacity By Volume And Production Value on November 6, 2018 at 11:49 am
Rapid Influenza Diagnostic Tests Market report focuses on rising market drifts to pinpoint market opportunities, to assist businesses and develop effective ways to optimize their market positions. The ... […]
- Infectious Disease Diagnostic Market on November 6, 2018 at 10:17 am
The infectious disease diagnostic market is segmented on the basis of product ... acquired methicillin-resistant staphylococcus aureus (MRSA) infection, and others (influenza, Ebola, typhoid, malaria, ... […]
- Loveland nurse becomes patient as influenza tests her on November 3, 2018 at 10:27 am
Shelly's final diagnosis ended up 11 items long ... metabolic encephalopathy, cardiogenic shock, influenza serotype B, influenza with streptococcus group A and bacteremia. "Very scary stuff, like a li... […]
via Google News and Bing News